Soluble lipidated ligand agents for treating eye inflammation
The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.
1. A method of treating inflammation in the eye, the method comprising administering to the eye of a subject in need thereof a soluble lipidated ligand agent that has the following structure:
wherein each of the Y, S, and A amino acids are D-amino acids, and wherein Tic represents (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
2. The method of claim 1 , wherein the soluble lipidated ligand agent is formulated as a pharmaceutical composition comprising the soluble lipidated ligand agent and a pharmaceutically acceptable carrier.
3. The method of claim 1 , wherein the soluble lipidated ligand agent is administered at an effective dose at an administration interval such that at least one symptom or feature of inflammation is reduced in intensity, severity, duration, or frequency or has delayed onset.
4. The method of claim 1 , wherein the soluble lipidated ligand entity is administered daily, twice a week, once a week, once every two weeks, once every three weeks, once a month, or at a variable interval.
5. The method of claim 1 , wherein the soluble lipidated ligand entity is administered topically.
6. A method of treating inflammation in the eye, the method comprising administering to the eye of a subject in need thereof a soluble lipidated ligand agent that has the following structure:
(SEQ ID NO.: 11), wherein one or more of the Y, S, and A amino acids are D-amino acids, and wherein Tic represents (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.